COVID-19 and the Heart and Vasculature
Bernard Kadosh, Michael Garshick, Juan Gaztañaga, Kathryn J. Moore, Jonathan Newman, Michael H. Pillinger, Ravichandran Ramasamy, Harmony R. Reynolds, Binita Shah, Judith S. Hochman, Glenn I. Fishman, Stuart D. Katz
Abstract
The coronavirus disease 2019 (COVID-19) pandemic presents an unprecedented challenge and opportunity for translational investigators to rapidly develop safe and effective therapeutic interventions. Greater risk of severe disease in COVID-19 patients with comorbid diabetes mellitus, obesity, and heart disease may be attributable to synergistic activation of vascular inflammation pathways associated with both COVID-19 and cardiometabolic disease. This mechanistic link provides a scientific framework for translational studies of drugs developed for treatment of cardiometabolic disease as novel therapeutic interventions to mitigate inflammation and improve outcomes in patients with COVID-19.